Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report)'s stock price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $6.38 and traded as low as $5.18. Syros Pharmaceuticals shares last traded at $5.56, with a volume of 287,306 shares traded.
Analyst Ratings Changes
Several research firms have weighed in on SYRS. StockNews.com downgraded shares of Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday. HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Syros Pharmaceuticals in a research note on Monday, April 1st. Finally, Piper Sandler restated an "overweight" rating and set a $13.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday, April 3rd.
Read Our Latest Report on Syros Pharmaceuticals
Syros Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 2.07, a quick ratio of 3.95 and a current ratio of 3.95. The firm's 50 day simple moving average is $6.34 and its 200 day simple moving average is $5.19. The firm has a market capitalization of $136.59 million, a price-to-earnings ratio of -0.89 and a beta of 1.74.
Hedge Funds Weigh In On Syros Pharmaceuticals
Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Syros Pharmaceuticals by 44.8% in the 4th quarter. Vanguard Group Inc. now owns 764,812 shares of the company's stock valued at $5,958,000 after purchasing an additional 236,620 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Syros Pharmaceuticals by 125.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 239,681 shares of the company's stock valued at $1,867,000 after purchasing an additional 133,149 shares during the period. Blue Owl Capital Holdings LP acquired a new position in shares of Syros Pharmaceuticals in the 4th quarter valued at $11,632,000. Opaleye Management Inc. acquired a new position in shares of Syros Pharmaceuticals in the 4th quarter valued at $2,799,000. Finally, Flagship Pioneering Inc. lifted its stake in shares of Syros Pharmaceuticals by 30.2% in the 4th quarter. Flagship Pioneering Inc. now owns 1,293,848 shares of the company's stock valued at $10,079,000 after purchasing an additional 300,000 shares during the period. 91.47% of the stock is currently owned by institutional investors and hedge funds.
About Syros Pharmaceuticals
(
Get Free Report)
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
See Also
Before you consider Syros Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syros Pharmaceuticals wasn't on the list.
While Syros Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.
Get This Free Report
